A novel orexin antagonist from a natural plant was discovered using zebrafish behavioural analysis

1) Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov 2011; 10: 507-519.

2) Bruni G, Lakhani P, Kokel D. Discovering novel neuroactive drugs through high-throughput be- havior-based chemical screening in the zebrafish. Front Pharmacol 2014; 5: 153.

3) DUBIŃSKA-MAGIERA M, DACZEWSKA M, LEWICKA A, MIGO-cka-Patrzałek M, Niedbalska-Tarnowska J, Jagla K. Zebrafish: a model for the study of toxicants affecting muscle development and function. Int J Mol Sci 2016; 17: 1941.

4) Khan KM, Collier AD, Meshalkina DA, Kysil EV, Khatsko SL, Kolesnikova T, Morzherin YY, Warnick JE, Kalueff AV, Echevarria D. Zebrafish models in neu- ropsychopharmacology and CNS drug discovery. Br J Pharmacol 2017; 174: 1925-1944.

5) Baraban SC, Dinday MT, Hortopan GA. Drug screen-ing in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Nat Commun 2013; 4: 2410.

6) Beuckmann CT, Yanagisawa M. Orexins: from neuro- peptides to energy homeostasis and sleep/wake regulation. J Mol Med 2002; 80: 329-342.

7) Chieffi S, Carotenuto M, Monda V, Valenzano A, Vil- lano I, Precenzano F, Tafuri D, Salerno M, Filippi N, Mollica MP, Lacono D, Nigro E, Monda M, Messina G, Messina A. Orexin system: the key for a healthy life. Front Physiol 2017; 8: 357.

8) Nixon JP, Mavanji V, Butterick TA, Billington CJ, Kotz CM, Teske JA. Sleep disorders, obesity, and aging: the role of orexin. Ageing Res Rev 2015; 20: 63-73.

9) Kornum BR, Faraco J, Mignot E. Narcolepsy with hypocretin/orexin deficiency, infections and auto- immunity of the brain. Curr Opin Neurobiol 2011; 21: 897-903.

10) Barateau L, Dauvilliers Y. Recent advances in treatment for narcolepsy. Ther Adv Neurol Disord 2019; 12: 1-12.

11) Citrome L. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int. J Clin Pract 2014; 68: 1429-1441.

12) Zhang B, Shimada Y, Kuroyanagi J, Nishimura Y, Umemoto N, Nomoto T, Shintou T, Miyazaki T, Tana-KA T. Zebrafish xenotransplantation model for cancer stem-like cell study and high-throughput screening of inhibitors. Tumour Biol 2014; 35: 11861-11869.

13) Westerfield MA. A guide for the laboratory use of zebrafish (Danio rerio). University of Oregon Press, 2007.

14) Nishimura Y, Okabe S, Sasagawa S, Murakami S, Ash-ikawa Y, Yuge M, Kawaguchi K, Kawase R, Tanaka T. Pharmacological profiling of zebrafish behavior using chemical and genetic classification of sleep- wake modifiers. Front Pharmacol 2015; 6: 257.

15) Bennett T, Bray D, Neville MW. Suvorexant, a dual orexin receptor antagonist for the management of insomnia. P T 2014; 39: 264-266.

16) Neubauer DN. Almorexant, a dual orexin receptor antagonist for the treatment of insomnia. Curr Opin Investig Drugs 2010; 11: 101-110.

17) Renzulli C, Nash M, Wright M, Thomas S, Zamuner S, Pellegatti M, Bettica P, Boyle G. Disposition and metabolism of [14C] SB-649868, an orexin 1 and 2 receptor antagonist, in humans. Drug Metab Dispos 2011; 39: 215-227.

18) Smart D, Sabido-David C, Brough SJ, Jewitt F, Johns A, Porter RA, Jerman JC. SB-334867-A: the first selective orexin-1 receptor antagonist. Br J Phar- macol 2001; 132: 1179-1182.

19) Langmead CJ, Jerman JC, Brough SJ, Scott C, Porter RA, HERDON HJ. Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br J Pharmacol 2004; 141: 340-346.

20) Gozzi A, Turrini G, Piccoli L, Massagrande M, Aman- tini D, Antolini M, Martinelli P, Cesari N, Montanari D, Tessari M, Corsi M, Bifone A. Functional mag- netic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists. PLoS One 2011; 6: e16406.

21) Hirose M, Egashira S, Goto Y, Hashihayata T, Ohtake N, Iwaasa H, Hata M, Fukami T, Kanatani A, Yamada K. N-acyl 6, 7-dimethoxy-1, 2, 3, 4-tetrahydroiso- quinoline: the first orexin-2 receptor selective non-peptidic antagonist. Bioorg Med Chem Lett 2003; 13: 4497-4499.

22) Roecker AJ, Reger TS, Mattern MC, Mercer SP, Berg- man JM, Schreier JD, Cube RV, Cox CD, Li D, Lemaire W, Bruno JG, Harrell CM, Garson SL, Gotter AL, Fox SV, Stevens J, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Stellabott J, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ. Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg Med Chem Lett 2014; 24: 4884-4890.

23) Wolber G, Dornhofer AA, Langer T. Efficient overlay of small organic molecules using 3D pharmacoph- ores. J Comput Aided Mol Des 2006; 20: 773-788.

24) Wolber G, Langer T. LigandScout: 3-D pharmaco- phores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model 2005; 45: 160-169.

25) Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res 2000; 28: 235-242.

26) Yin J, Babaoglu K, Brautigam CA, Clark L, Shao Z, Scheuermann TH, Harrell CM, Gotter AL, Roecker AJ, Winrow CJ, Renger JJ, Coleman PJ, Rosenbaum DM. Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors. Nat Struct Mol Biol 2016; 23: 293-299.

27) Yin J, Mobarec JC, Kolb P, Rosenbaum DM Yin. Crys-tal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant. Nature 2015; 519: 247-250. A novel orexin antagonist from a natural plant was discovered using zebrafish behavioural analysis

28) Ruiz-Carmona S, Alvarez-Garcia D, Foloppe N, Gar-mendia-Doval AB, Juhos S, Schmidtke P, Barril X, Hubbard RE, Morley SD. rDock: a fast, versatile and open source program for docking ligands to proteins and nucleic acids. PLoS Comput Biol 2014; 10: e1003571.

29) Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol 2013; 30: 772-780.

30) Rognan D. The impact of in silico screening in the discovery of novel and safer drug candidates. Pharmacol Ther 2017; 175: 47-66.

31) Bryant PA, Trinder J, Curtis N. Sick and tired: Does sleep have a vital role in the immune system? Nat Rev Immunol 2004; 4: 457-467.

32) Krueger JM, Rector DM, Churchill L. Sleep and cytokines. Sleep Med Clin 2007; 2: 161-169.

33) OPP MR. Cytokines and sleep. Sleep Med Rev 2005; 9: 355-364.

34) Clark IA, Vissel B. Inflammation-sleep interface in brain disease: TNF, insulin, orexin. J Neuroinflam 2014; 11: 51.

35) DeLano WL. The PyMOL molecular graphics sys- tem. DeLano Scientific, 2012.